Surface-enhanced Raman spectroscopy (SERS) has emerged as a transformative tool in biomedical diagnostics, offering a highly sensitive and non-invasive method for detecting molecular biomarkers at exceptionally low concentrations. This approach takes advantage of the plasmonic characteristics of customized metallic nanostructures that produce intense localized electromagnetic fields via localized surface plasmon resonance and facilitate electron transfer reactions that notoriously enhance the intrinsically weak Raman scattering signals of molecular entities which reside on or next to their surfaces. SERS-based assays have shown remarkable potential in detecting cancer biomarkers, circulating tumor DNA (ctDNA), and proteins at early stages, enabling timely and targeted intervention. Additionally, the combination of SERS with AI-driven data analysis has facilitated real-time diagnostics, enhancing the precision and efficiency of point-of-care testing. Despite its promising capabilities, challenges such as substrate fouling, signal degradation, and the need for better biocompatibility remain. Nevertheless, ongoing research in substrate development, coupled with advances in AI, positions SERS as a leading technology for future diagnostic tools. This paper explores the current state of SERS in biomedical applications, highlighting its potential to revolutionize diagnostics and personalized medicine while addressing the existing limitations and future research directions.
Razaq et al. (Wed,) studied this question.